TOE1 Human Pre-designed siRNA Set A contains three designed siRNAs for TOE1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tolfenamic Acid (Standard) is the analytical standard of Tolfenamic Acid. This product is intended for research and analytical applications. Tolfenamic Acid (GEA 6414) is a non-steroidal anti-inflammatory and anti-cancer agent, selectively inhibits COX-2, with an IC50 of 13.49 μM (3.53 μg/mL) in LPS-treated (COX-2) canine DH82 monocyte/macrophage cells, but shows no effect on COX-1.

TOLLIP Human Pre-designed siRNA Set A contains three designed siRNAs for TOLLIP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tolnaftate (Standard) is the analytical standard of Tolnaftate. This product is intended for research and analytical applications. Tolnaftate (NP-27) is a synthetic thiocarbamate used as an anti-fungal agent. .

Tolterodine (tartrate) (Standard) is the analytical standard of Tolterodine (tartrate). This product is intended for research and analytical applications. Tolterodine Tartrate (Kabi-2234; PNU-200583E) is a potent muscarinic receptor antagonist and shows selectivity for the urinary bladder over salivary glands in vivo.

Toltrazuril-d3 is deuterated labeled Toltrazuril. Toltrazuril (BAY-i 9142) is an antiprotozoal agent that acts upon Coccidia parasites.

TOM1 Human Pre-designed siRNA Set A contains three designed siRNAs for TOM1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TOM1L1 Human Pre-designed siRNA Set A contains three designed siRNAs for TOM1L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TOM1L2 Human Pre-designed siRNA Set A contains three designed siRNAs for TOM1L2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tominersen sodium is a second-generation 2′-O-(2-methoxyethyl) antisense oligonucleotide that targets huntingtin protein (HTT) mRNA and potently suppresses HTT production. Tominersen improves survival and reduces brain atrophy in mice. Tominersen sodium can be used for the research of Huntington’s disease (HD)[1][2].

Tominersen sodium is a second-generation 2′-O-(2-methoxyethyl) antisense oligonucleotide that targets huntingtin protein (HTT) mRNA and potently suppresses HTT production. Tominersen improves survival and reduces brain atrophy in mice. Tominersen sodium can be used for the research of Huntington’s disease (HD)[1][2].

Tominersen sodium is a second-generation 2′-O-(2-methoxyethyl) antisense oligonucleotide that targets huntingtin protein (HTT) mRNA and potently suppresses HTT production. Tominersen improves survival and reduces brain atrophy in mice. Tominersen sodium can be used for the research of Huntington’s disease (HD)[1][2].

TOMM20 Human Pre-designed siRNA Set A contains three designed siRNAs for TOMM20 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TOMM22 Human Pre-designed siRNA Set A contains three designed siRNAs for TOMM22 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TOMM34 Human Pre-designed siRNA Set A contains three designed siRNAs for TOMM34 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TOMM40 Human Pre-designed siRNA Set A contains three designed siRNAs for TOMM40 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TOMM40L Human Pre-designed siRNA Set A contains three designed siRNAs for TOMM40L gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TOMM5 Human Pre-designed siRNA Set A contains three designed siRNAs for TOMM5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TOMM6 Human Pre-designed siRNA Set A contains three designed siRNAs for TOMM6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TOMM7 Human Pre-designed siRNA Set A contains three designed siRNAs for TOMM7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TOMM70 Human Pre-designed siRNA Set A contains three designed siRNAs for TOMM70 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TOMT Human Pre-designed siRNA Set A contains three designed siRNAs for TOMT gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TONSL Human Pre-designed siRNA Set A contains three designed siRNAs for TONSL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Toosendanin/BSA is one of protein/peptide and small molecule drug conjugates (PDCs), consisting of Toosendanin (HY-N0263) and BSA. PCDs are promising targeted therapeutics with better cell permeability and drug selectivity than antibody-drug conjugates (ADCs). PDCs have been widely used in research on cancer, COVID-19, and metabolic diseases[1].

Toosendanin/OVA is one of protein/peptide and small molecule drug conjugates (PDCs), consisting of Toosendanin (HY-N0263) and OVA. PCDs are promising targeted therapeutics with better cell permeability and drug selectivity than antibody-drug conjugates (ADCs). PDCs have been widely used in research on cancer, COVID-19, and metabolic diseases[1].

TOP1 Human Pre-designed siRNA Set A contains three designed siRNAs for TOP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Top1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Top1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Top1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Top1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

TOP1MT Human Pre-designed siRNA Set A contains three designed siRNAs for TOP1MT gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TOP2A Human Pre-designed siRNA Set A contains three designed siRNAs for TOP2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Top2a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Top2a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Top2a Rat Pre-designed siRNA Set A contains three designed siRNAs for Top2a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

TOP2B Human Pre-designed siRNA Set A contains three designed siRNAs for TOP2B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TOP3A Human Pre-designed siRNA Set A contains three designed siRNAs for TOP3A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TOP3B Human Pre-designed siRNA Set A contains three designed siRNAs for TOP3B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TOPAZ1 Human Pre-designed siRNA Set A contains three designed siRNAs for TOPAZ1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TOPBP1 Human Pre-designed siRNA Set A contains three designed siRNAs for TOPBP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TOPOI/PARP-1-IN-1 (Compound B6) is an orally active, low cytotoxic TOPOI/PARP dual inhibitor with an IC50 value of 0.09 μM for PARP1. TOPOI/PARP-1-IN-1 can effectively inhibit the proliferation and migration of cancer cells. TOPOI/PARP-1-IN-1 also causes cell cycle arrest in the G0/G1 phase and induces apoptosis. The tumor growth inhibition rate (TGI) of TOPOI/PARP-1-IN-1 in mice […]

Topoisomerase I inhibitor 14 (Compound 4h) is an inhibitor for Topoisomerase I. Topoisomerase I inhibitor 14 inhibits proliferation of A549 and C6 with IC50s of 4.56 μM and 13.17 μM, without significant toxicity in healthy cells NIH3T3 (IC50 is 74.44 μM), which exhibits anticancer potency[1].

Topoisomerase I inhibitor 15 (compound 4b) is an inhibitor of topoisomerase I with anticancer activity. Topoisomerase I inhibitor 15 inhibits A549 cells with an IC50 of 7.34 μM[1].

Topoisomerase I inhibitor 21 (Compound 3e) is an inhibitor for Topoisomerase I through stabilization of enzyme-DNA complex. Topoisomerase I inhibitor 21 exhibits antiproliferative activity in 39 human cancer cells (JFCR39) with mean GI50 39 nM[1].

Topoisomerase II inhibitor 1 (compound 89) is a highly efficient and selective topoisomerase IIα inhibitor[1].